Treatment and outcome of invasive bladder cancer in patients after renal transplantation
Treatment and outcome of invasive bladder cancer in patients after renal transplantation
复制标题
DOI：
10.1097/01.ju.0000110612.42382.0a
复制
发表时间：
2004-03-01
影响因子：
6.6
通讯作者：
Carroll, PR
中科院分区：
文献类型：
--
作者：
Master, VA;Meng, MV;Carroll, PR
目的：肾移植受者膀胱癌的最佳治疗和临床结局尚未明确。我们分析了单一机构的治疗策略和结果，这些patients.Materials和方法：我们回顾性地回顾了加州大学，旧金山弗朗西斯科移植数据库，其中包含1964年和2002年之间进行的6,288肾移植的信息。还查询了器官共享联合网络数据库和以色列宾州国际移植肿瘤登记处，以描述肾移植受者膀胱癌的全球性质。结果：器官共享联合网络数据库（1986年至2001年）载有31名被发现患有膀胱癌的病人的资料（0.024%的患病率）和以色列宾夕法尼亚国际移植肿瘤登记处（1967年至2001年）包含的135例患者的信息，占所有报告的恶性肿瘤的0.84%。我们确定了7名肾移植受者在我们的机构与膀胱癌。5例患者在移植后中位2.8年发生浸润性移行细胞癌。3例患者接受了无并发症的根治性膀胱切除术和保留移植肾。48个月总生存率为60%。结论：肾移植后膀胱癌并不常见。对于浸润性疾病的患者，应考虑传统的摘除性手术。此外，同种异体移植物很少是移行细胞癌的来源，可以保留。根据我们的经验，治疗后癌症和泌尿系统的结果优于非移植患者的结果。
Purpose: Optimal management and clinical outcome of bladder cancer in renal transplant recipients are not well-defined. We analyzed single institution treatment strategies and outcomes of these patients.Materials and Methods: We retrospectively reviewed the University of California, San Francisco transplant database which contains information on 6,288 renal transplants performed between 1964 and 2002. The United Network for Organ Sharing database and Israel Penn International Transplant Tumor Registry were also queried to characterize the global nature of bladder cancer in renal transplant recipients.Results: The United Network for Organ Sharing database (1986 to 2001) contained information on 31 patients who were found to have bladder cancer (0.024% prevalence) and the Israel Penn International Transplant Tumor Registry (1967 to 2001) contained information on 135 patients representing 0.84% of all reported malignancies. We identified 7 renal transplant recipients with bladder cancer at our institution. Invasive transitional cell carcinoma developed in 5 patients at a median of 2.8 years after transplant. Three patients underwent uncomplicated radical cystectomy and preservation of the renal allograft. Overall survival at 48 months was 60%.Conclusions: Bladder cancer after renal transplantation is not common. For patients who present with invasive disease, traditional extirpative surgery should be considered. Moreover, the allograft is rarely the source of transitional cell carcinoma and can be preserved. In our experience the cancer and urinary outcomes compare favorably with nontransplant patient outcomes after treatment.